康柏西普联合玻璃体切除术治疗增殖期糖尿病性视网膜病变的临床疗效<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2024.01.003

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1157 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the clinical effect of conbercept combined with vitrectomy (PPV) in the treatment of proliferative diabetic retinopathy (PDR). 【Methods】 Totally 46 patients (50 eyes) with PDR, who visited our hospital from August 2020 to October 2022, were selected as the study subjects, and they were randomly divided into two groups. There were 23 patients (25 eyes) in the conventional group who were treated with 23 G PPV alone and 23 patients (25 eyes) in the study group who were treated with conbercept-assisted 23 G PPV. Postoperative follow-up included a comparison of surgical duration and changes in intraoperative and postoperative conditions between the two groups. 【Results】 The average surgical duration in the study group was significantly lower than that in the conventional group (t=2.47, P<0.05). Postoperatively, the best corrected visual acuity (BCVA) in the study group was higher than that in the conventional group. Additionally, the rates of iatrogenic retinal break and retinal detachment treated with silicone oil tamponade were lower in the study group if compared to the conventional group (P<0.05). 【Conclusion】 PDR patients treated with conbercept-assisted 23 G PPV can effectively reduce surgical duration, enhance postoperative visual acuity, and decrease the incidence of complications.

Key words： Diabetic Retinopathy/CO Diabetes Mellitus, Type 2/CO Vitrectomy Angiogenesis Inhibitors/TU

Received: 24 November 2023

PACS:

R587.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Huiyan
	HU Peng
	JIANG Lijuan
	et al

Cite this article:

WANG Huiyan,HU Peng,JIANG Lijuan, et al. Clinical Effects of Conbercept in Combination with Vitrectomy for Proliferative Diabetic Retinopathy[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(1): 11-13.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.01.003 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I1/11

[1] 杨健, 杨凤娟, 苗晓, 等. 糖尿病性视网膜病变发生机制研究进展[J].中国老年学杂志, 2017, 37(18): 4680-4682.
[2] 林绍冰. PPV术前玻璃体腔注射康柏西普对PDR患者并发症和视力恢复的影响[J].国际眼科杂志, 2018, 18(5): 919-921.
[3] 赵辉,邵晓涵. 2型糖尿病患者血清镁、糖化白蛋白与增殖性糖尿病性视网膜病变发生的相关性分析[J].医学临床研究, 2022, 39(2): 198-200.
[4] 李燕龙, 董晓. 康柏西普玻璃体腔注射联合眼底激光光凝治疗糖尿病性黄斑水肿的效果[J].临床医学研究与实践, 2019, 4(32): 109-111.
[5] 张敏, 曹文娟. 玻璃体腔注射雷珠单抗或康柏西普联合PRP治疗增生性糖尿病视网膜病变的效果[J].临床医学研究与实践, 2023, 8(23): 77-80.
[6] WEI Y M, YAN J, YANG H X. Identification of severe gestational diabetes mellitus after new criteria used in China[J].J Perinatol,2016, 36(2): 90-94.
[7] 伊恩晖, 杜兆江, 杨格强, 等. 玻璃体内注射康柏西普在中重型非增殖期糖尿病视网膜病变合并白内障手术患者中的应用效果[J].临床医学研究与实践, 2022, 7(12): 17-21.
[8] 马春红. 增殖性糖尿病视网膜病变行玻璃体切割术的护理[J].世界最新医学信息文摘, 2018, 18(25): 234-240.
[9] 陈小红, 王云鹏, 陈梅珠. VEGF在糖尿病性视网膜病变发病机制中的作用及抗VEGF治疗新进展[J].眼科新进展, 2015, 35(7): 692-696.
[10] 李玉国. 康柏西普与雷珠单抗治疗早产儿视网膜病变的临床效果比较[J].医学理论与实践, 2023, 36(19): 3342-3344.
[11] 梁道桐, 陈达钻, 黄立,等. 稳定控制血糖联合康柏西普玻璃体腔注射治疗增殖性糖尿病性视网膜病变临床观察[J].内科, 2017, 12(4): 458-460.
[12] MOHARRAM H M, ABDELHALIM A S, HAMID M A, et al. Comparison between silicone oil and gas in tamponading giant retinal breaks[J].Clin Ophthalmol,2020, 14(1):27-32.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(2): 302-304.